Resverlogix Issues a Management Statement



    TSX Exchange Symbol: RVX

    CALGARY, Oct. 7 /CNW/ - Resverlogix Corp. ("Resverlogix" or the
"Company") (TSX:RVX) announced today that in light of the recent significant
market drop of Resverlogix shares management feels it is prudent to restate
that the company fundamentals remain the same if not stronger in regards to
the Company's science and business developments. There is no reason for the
price drop other than the current global conditions. Management will present
an update as to the current business development discussions at the Annual
General Meeting on October 28th, at the Telus Convention Centre in Calgary
Alberta at 2:00pm

    About Resverlogix Corp.

    Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and
other vascular disorders. The Company's secondary focus is TGF-Beta
Shield(TM), a program that aims to address burgeoning grievous diseases, such
as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange
(TSX:RVX). For further information please visit www.resverlogix.com.

    This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.

    %SEDAR: 00019253E




For further information:

For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Email: Theresa@resverlogix.com;
Donald McCaffrey, President & CEO, Resverlogix Corp., Phone: (403) 254-9252,
Email: Don@resverlogix.com; Website: www.resverlogix.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890